Benzinga | Jan 31, 2022 08:42AM EST

Morgan Stanley Upgrades Legend Biotech to Overweight, Announces $51 Price Target

Morgan Stanley analyst Matthew Harrison upgrades Legend Biotech (NASDAQ:LEGN) from Equal-Weight to Overweight and announces $51 price target.